 Germany and Austria) it is a standard therapy.In the United States, ABVD (or Stanford V) is generally given instead, because BEACOPP is perceived by practicing oncologists to have the potential to induce more secondary neoplasias (such as leukemias).However, the final results from the GHSG HD14 trial indicate that "there
were no overall differences in treatment-related mortality or secondary malignancies" of BEACOPP relative to ABVD.